Publications

2022

Codiversification of gut microbiota with humans.

Suzuki, T. A., Fitzstevens, L., Schmidt, V.T.,  Enav‚ H., Huus, K. E., Mbong Ngwese, M., Grießhammer, A., Pfleiderer, A., Adegbite, B., R., Zinsou, J. F., Esen, M., Velavan, T., P., Adegnika, A. A., Huu Song, L., Spector, T. D., Muehlbauer, A. L., Marchi, N., Kang, H., Maier, L., Blekhman, R., Ségurel, L., Ko, G., Youngblut, N. D., Kremser, P., Ley, R. E.  (2022).

Science, 377, pages 1328-1332

2021

Unravelling the collateral damage of antibiotics on gut bacteria.

Maier, L.#*, Goemans, C. V.*, Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Müller, P., Garcia-Santamarina, S., Cacace, E., Zhang, B., Gekeler, C., Banerjee, T., Anderson, E. E., Milanese, A., Löber, U., Forslund, S. K., Patil, K. R., Zimmermann, M., Stecher, B., … Typas, A.# (2021).

Nature, 599, pages 120-124

Bioaccumulation of therapeutic drugs by human gut bacteria.

Klünemann, M., Andrejev, S., Blasche, S., Mateus, A., Phapale, P., Devendran, S., Vappiani, J., Simon, B., Scott, T. A., Kafkia, E., Konstantinidis, D., Zirngibl, K., Mastrorilli, E., Banzhaf, M., Mackmull, M.-T., Hövelmann, F., Nesme, L., Brochado, A. R., Maier, L., … Patil, K. R. (2021).

Nature, 597, 533-538

Towards a mechanistic understanding of reciprocal drug-microbiome interactions.

Zimmermann, M.#, Patil, K. R., Typas, A., & Maier, L.# (2021).

Molecular Systems Biology, 17(3), e10116.

2019

Escherichia coli limits Salmonella Typhimurium infections after diet shifts and fat-mediated microbiota perturbation in mice.

Wotzka, S. Y., Kreuzer, M., Maier, L., Arnoldini, M., Nguyen, B. D., Brachmann, A. O., Berthold, D. L., Zünd, M., Hausmann, A., Bakkeren, E., Hoces, D., Gül, E., Beutler, M., Dolowschiak, T., Zimmermann, M., Fuhrer, T., Moor, K., Sauer, U., Typas, A., … Hardt, W.-D. (2019).

Nature Microbiology, 4(12), 2164–2174.

Komplexe Wechselwirkungen zwischen Arzneimitteln und dem Mikrobiom.

Maier, L. (2019). 

BIOspektrum, 25(7), 707–710.

2018

Microbiota stability in healthy individuals after single-dose lactulose challenge—A randomized controlled study.

Wotzka, S. Y.*, Kreuzer, M.*, Maier, L.*, Zünd, M., Schlumberger, M., Nguyen, B., Fox, M., Pohl, D., Heinrich, H., Rogler, G., Biedermann, L., Scharl, M., Sunagawa, S., Hardt, W.-D., & Misselwitz, B. (2018).

PLOS ONE, 13(10), e0206214.

Extensive impact of non-antibiotic drugs on human gut bacteria.

Maier, L.*, Pruteanu, M.*, Kuhn, M.*, Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., Patil, K. R., Bork, P., & Typas, A. (2018).

Nature, 555(7698), 623–628.

2017

Systematically investigating the impact of medication on the gut microbiome.

Maier, L., & Typas, A. (2017).

Current Opinion in Microbiology, 39, 128–135.

Salt-responsive gut commensal modulates TH17 axis and disease.

Wilck, N., Matus, M. G., Kearney, S. M., Olesen, S. W., Forslund, K., Bartolomaeus, H., Haase, S., Mähler, A., Balogh, A., Markó, L., Vvedenskaya, O., Kleiner, F. H., Tsvetkov, D., Klug, L., Costea, P. I., Sunagawa, S., Maier, L., Rakova, N., Schatz, V., … Müller, D. N. (2017).

Nature, 551(7682), 585–589.

2015

Granulocytes Impose a Tight Bottleneck upon the Gut Luminal Pathogen Population during Salmonella Typhimurium Colitis.

Maier, L., Diard, M., Sellin, M. E., Chouffane, E.-S., Trautwein-Weidner, K., Periaswamy, B., Slack, E., Dolowschiak, T., Stecher, B., Loverdo, C., Regoes, R. R., & Hardt, W.-D. (2014).

PLoS Pathogens, 10(12), e1004557.

Salmonella Typhimurium Strain ATCC14028 Requires H2-Hydrogenases for Growth in the Gut, but Not at Systemic Sites.

Maier, L., Barthel, M., Stecher, B., Maier, R. J., Gunn, J. S., & Hardt, W.-D. (2014).

PLoS ONE, 9(10), e110187.

2013

“Blooming” in the gut: How dysbiosis might contribute to pathogen evolution.

Stecher, B., Maier, L., & Hardt, W.-D. (2013).

Nature Reviews. Microbiology, 11(4), 277–284.

Microbiota-Derived Hydrogen Fuels Salmonella Typhimurium Invasion of the Gut Ecosystem.

Maier, L., Vyas, R., Cordova, C. D., Lindsay, H., Schmidt, T. S. B., Brugiroux, S., Periaswamy, B., Bauer, R., Sturm, A., Schreiber, F., von Mering, C., Robinson, M. D., Stecher, B., & Hardt, W.-D. (2013).

Cell Host & Microbe, 14(6), 641–651.

Stabilization of cooperative virulence by the expression of an avirulent phenotype.

Diard, M., Garcia, V., Maier, L., Remus-Emsermann, M. N. P., Regoes, R. R., Ackermann, M., & Hardt, W.-D. (2013).

Nature, 494(7437), 353–356.

2012

Live attentuated S. Typhimurium vaccine with improved safety in immuno-compromised mice. 

Periaswamy, B., Maier, L., Vishwakarma, V., Slack, E., Kremer, M., Andrews-Polymenis, H. L., McClelland, M., Grant, A. J., Suar, M., & Hardt, W.-D. (2012).

PloS One, 7(9), e45433.

Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not.

Endt, K.*, Maier, L.*, Käppeli, R., Barthel, M., Misselwitz, B., Kremer, M., & Hardt, W.-D. (2012).

Antimicrobial Agents and Chemotherapy, 56(5), 2295–2304.

Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae.

Stecher, B., Denzler, R., Maier, L., Bernet, F., Sanders, M. J., Pickard, D. J., Barthel, M., Westendorf, A. M., Krogfelt, K. A., Walker, A. W., Ackermann, M., Dobrindt, U., Thomson, N. R., & Hardt, W.-D. (2012).

PNAS, 109(4), 1269–1274.

2010

Glycosylation of wall teichoic acid in Staphylococcus aureus by TarM.

Xia, G., Maier, L., Sanchez-Carballo, P., Li, M., Otto, M., Holst, O., & Peschel, A. (2010).

The Journal of Biological Chemistry, 285(18), 13405–13415.

————————————————————————————————————————

* equal contribution, # corresponding authors